Photo by nci from unsplash
Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front‐line setting and as later‐line treatment. However, knowledge about the outcomes and adverse events (AE) among… Click to show full abstract
Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front‐line setting and as later‐line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population‐based level is still limited.
Keywords:
real world;
lymphocytic leukemia;
outcomes 205;
world outcomes;
chronic lymphocytic
Journal Title: European Journal of Haematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!